Clinical Trial Update: Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy [Phase 1]

View source ↗

Summary

Phase 1 safety and tolerability study of RN6G in subjects with advanced dry age-related macular degeneration including geographic atrophy has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• RN6G

Snippet

Sponsor: Pfizer | Conditions: Age-Related Maculopathy, Age-Related Maculopathies | Phase 1 | Status: COMPLETED | Results posted: 2022-05-12